ALKS
Alkermes Inc. plc
Nasdaq · usd
Alkermes Inc. plc (ALKS) trades at $43.63 (-1.24%) as of 7:30:04 PM EDT on Oct 23, 2026, +6.96% over the past month. Market cap is $7.41B, with 6.3 days to cover in short interest.
Stock performance
How Alkermes Inc. plc (ALKS) stock has performed from one day to one year, with its 52-week range.
- 1D
- -1.24%
- 1W
- +5.85%
- 1M
- +6.96%
- YTD
- +55.93%
- 1Y
- +46.80%
- 52-wk range
- $27.00 – $55.67
Key statistics
Today's trading snapshot for ALKS: day range, open, previous close, volume and market cap.
- Day range
- $43.15 – $44.15
- Open
- $44.15
- Prev close
- $44.18
- Volume
- 872.9K
- Market cap
- $7.41B
- Shares out
- 167.76M
Valuation and profitability ratios: P/E, P/S, ROE
Valuation and profitability ratios for Alkermes Inc. plc: P/E, P/S, P/B, ROE and more.
- P/E
- 112.09
- P/S
- 4.44
- P/B
- 4.10
- P/FCF
- 33.44
- ROE
- 3.7%
- ROA
- 1.5%
- Debt/Equity
- 0.83
- Div yield
- 0.00%
As of Oct 22, 2026
8-K filings
Material corporate events Alkermes Inc. plc has disclosed to the SEC on Form 8-K.
- Business developmentsSep 21, 2026
On September 21, 2026, the Company announced positive topline results from a phase 1 proof-of-concept study evaluating ALKS 7290, the Company's novel, investigational orexin 2 receptor (OX2R) agonist in development for the treatment of attention-deficit hyperactivity disorder (ADHD).
- Board of directorsSep 16, 2026
On September 14, 2026, the board of directors (the "Board") of Alkermes plc (the "Company") increased the size of the Board from ten (10) to eleven (11) directors and appointed Anne C. Whitaker to the Board, effective immediately, with an initial term expiring at the Company's 2027 annual general meeting of shareholders. As of the date of this Current Report on Form 8-K, Ms. Whitaker has not been appointed to any committee of the Board.
- Debt activityAug 12, 2026
On August 12, 2026, Alkermes plc entered into Amendment No. 1 to Credit Agreement, which amends the Credit Agreement dated as of February 12, 2026. The Amendment reduces the interest rate spread (i) under the TLA Facility by 0.75% and (ii) under the TLB Facility by 0.50%, among other changes.
- Guidance and outlookJul 28, 2026
On July 28, 2026, Alkermes plc (the "Company") announced financial results for the three and six months ended June 30, 2026 and updated certain financial expectations for the year ending December 31, 2026.
- Deal terminationsJul 8, 2026
On July 6, 2026, Alkermes plc (the "Company") and Amneal Pharmaceuticals LLC ("Amneal") terminated the previously disclosed Authorized Generic Product Supply Agreement entered into on September 9, 2025 (the "Agreement").
ALKS short interest
How heavily ALKS is shorted: shares short, days to cover and average daily volume.
- Days to cover
- 6.3
- Short interest
- 17.82M
- Avg volume
- 2.84M
As of · reported to FINRA twice monthly.
ALKS news
The latest news and headlines about Alkermes Inc. plc (ALKS).
- HRMY Stock Gains 27.6% in Six Months: Is There More Room for Growth?positiveZacks Investment Research· Oct 16, 2026
- 4 CNS Drug Stocks Worth Watching This World Mental Health DaypositiveZacks Investment Research· Oct 9, 2026
- Global Substance Use Disorder Treatment Market Analysis and Forecast to 2030 | Long-Acting Therapies, Telemedicine, and Drug Innovation Drive GrowthpositiveGlobeNewswire Inc.· Oct 2, 2026
- Alkermes Posts Positive Data From Phase I ADHD Study on ALKS 7290positiveZacks Investment Research· Sep 22, 2026
- Alcohol Use Disorder Market Set to Expand at a 12.1% CAGR During the Forecast Period (2026–2036), Owing to the Emergence of Novel Mechanisms Such as 5-HT3 Pathway, NOP Receptor, mGluR5 NAM, and Other | DelveInsightpositiveGlobeNewswire Inc.· Jun 8, 2026
Frequently asked questions
What is the Alkermes Inc. plc (ALKS) stock price today?
Alkermes Inc. plc (ALKS) is trading at $43.63 (-1.24% on the day) as of 7:30:04 PM EDT on Oct 23, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.
What is Alkermes Inc. plc?
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas.
What is the short interest in ALKS?
As of Sep 30, 2026, ALKS has 17.82M shares short and 6.3 days to cover.
What exchange is ALKS listed on?
Alkermes Inc. plc (ALKS) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.
Build with AI
Build an analysis of ALKS with your agent
Point Claude or ChatGPT at the Massive MCP server and recreate this page from live data.
Connect the Massive MCP server (API reference: massive.com/docs/llms.txt) and build a ALKS analysis: the latest quote, key ratios (P/E, P/S, ROE), short interest, recent insider activity and the latest news.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.